Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Current Assets: 2010-2024

Historic Current Assets for Ani Pharmaceuticals (ANIP) over the last 15 years, with Dec 2024 value amounting to $527.7 million.

  • Ani Pharmaceuticals' Current Assets rose 33.97% to $698.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $698.4 million, marking a year-over-year increase of 33.97%. This contributed to the annual value of $527.7 million for FY2024, which is 1.51% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Current Assets of $527.7 million as of FY2024, which was up 1.51% from $519.8 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Current Assets registered a high of $527.7 million during FY2024, and its lowest value of $170.3 million during FY2020.
  • In the last 3 years, Ani Pharmaceuticals' Current Assets had a median value of $519.8 million in 2023 and averaged $463.9 million.
  • In the last 5 years, Ani Pharmaceuticals' Current Assets dropped by 9.26% in 2020 and then spiked by 88.92% in 2021.
  • Yearly analysis of 5 years shows Ani Pharmaceuticals' Current Assets stood at $170.3 million in 2020, then soared by 88.92% to $321.8 million in 2021, then rose by 6.99% to $344.3 million in 2022, then soared by 50.99% to $519.8 million in 2023, then rose by 1.51% to $527.7 million in 2024.